A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer

M. J. Lind*, S. Gomm, A. P. Simmonds, L. Ashcroft, A. Kamthan, H. Gurney, N. Thatcher

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


A total of 45 patients with advanced non-small-cell lung cancer were treated with a combination of 1.5 g/m2 ifosfamide given on days 1-5 every 3 weeks for four courses with 3 million IU a2b-interferon (Intron A) given s.c. three times a week for 12 weeks. Nine objective responses were seen, including two complete responses (CRs) and seven partial responses (PRs). Haematological and non-haematological toxicities were generally mild and did not necessitate discontinuation of therapy.

Original languageEnglish
Pages (from-to)142-144
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Issue number2
Publication statusPublished - Mar 1991
Externally publishedYes


Dive into the research topics of 'A phase II study of ifosfamide and a<sub>2b</sub>-interferon in advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this